Mov Disord Vol 34, Suppl 2 Archives - Page 196 of 217 - MDS Abstracts

2019 International Congress
Is safinamide helpful in multiple system atrophy?
R. Simões, A. Gonçalves, JJ. Ferreira (Lisboa, Portugal)
Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…
2019 International Congress
Quantifying eye and gait abnormalities in Parkinson’s patients after Deep brain stimulation
Z. Su, M. Brzezick, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)
Objective: To examine the usefulness of precise measurements of gait and eye movements as a means of quantifying PD. The aim is to identify and…
2019 International Congress
Using Quantitative Susceptibility Mapping to Predict Dementia in Parkinson’s Disease
G. Thomas, L. Leyland, J. Acosta-Cabronero, R. Weil (London, United Kingdom)
Objective: To investigate how brain iron deposition relates to visual function and dementia risk in Parkinson’s Disease (PD). Background: Oxidative stress due to brain iron…
2019 International Congress
Amylin single-nucleotide polymorphism and Parkinson’s disease
R. Valenti-Azcarate, I. Martinez-Valbuena, I. Marcilla Garcia, G. Marti, M. Carmona-Abellan, MT. Tuñon-Alvarez, MT. Luquin-Piudo (Pamplona, Spain)
Objective: The objective of this study was to evaluate if a single nucleotide polymorphism (SNP) in the amylin sequence is present in patients with Parkinson’s…
2019 International Congress
Measuring progression of nigrostriatal degeneration in Parkinson’s disease using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET
S. Xu, V. Dore, P. Alexander, Y. Lie, S. Bozinovski, R. Mulligan, K. Young, V. Villemagne, C. Rowe (Melbourne, Australia)
Objective: To evaluate the progression of nigrostriatal degeneration in participants with Parkinson’s disease (PD) using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET. Background: Vesicular monoamine…
2019 International Congress
Clinical features of constipation in patients with Parkinson’s disease: a cross-sectional study in China
LP. Zhu, XT. Zhou, Z. Zhou, LJ. Fang, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)
Objective: This study was designed to explore the clinical features of constipation, and investigate the risk factors of constipation in Chinese PD patients. Background: Constipation…
2019 International Congress
Puzzle resolution as cognitive test in Parkinson´s disease patients
C. Borrue-Fernandez, D. Santos-García, J. Pagonabarraga, B. Pascual-Sedano, M. Mata, C. Study Group (Madrid, Spain)
Objective: To analyze the value of puzzle resolution for cognitive testing in Parkinson´s disease patients. Background: Cognitive decline and dementia are common among Parkinson disease…
2019 International Congress
“Best practice” guidelines for the collection and analysis of speech data in patients with Parkinson’s Disease (PD).
E. Tripoliti, L. Ramig (Boulder Colorado, CO, USA)
Objective: To discuss the literature for collection and analysis of speech data for patients with PD in order to create “best practice” guidelines. Background: Speech…
2019 International Congress
Neuroprotective actions of red propolis extract and formononetin in a rat model of Parkinson’s disease
M. Gomes, S. Barroso, J. de Oliveira, D. Marques, A. Santos, J. Cardoso (Aracaju, Brazil)
Objective: To evaluate the effects of the hydroalcoholic extract of red propolis (HERP) and one of its major compounds, formononetin (FN), against the motor symptoms…
2019 International Congress
Serotonergic function in De Novo Parkinson’s Disease
HK. Park, JJ. Lee, YM. Park (Goyang, Republic of Korea)
Objective: We aimed to investigate the central serotonergic function in de novo PD and change in serotonergic function with dopaminergic medications. Background: While dopaminergic dysfunction…